How many 8-K filings has Vor Biopharma Inc. filed?

Vor Biopharma Inc. (VOR) has 28 8-K (Current Event Report) filings on record, spanning Jan 2024 to Mar 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Vor Biopharma Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Vor Biopharma Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Vor Biopharma Inc. (VOR) — 8-K Filings

All 8-K filings from Vor Biopharma Inc.. Browse 28 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (28)

Vor Biopharma Files 8-K: Material Agreement & Equity Sales — Mar 27, 2026 Risk: medium
On March 26, 2026, Vor Biopharma Inc. entered into a material definitive agreement and announced unregistered sales of equity securities. The company also provi
Vor Biopharma Files 8-K: Agreements, Equity Sales, Officer Changes — Dec 18, 2025 Risk: medium
On December 15, 2025, Vor Biopharma Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement, unregist
8-K Filing — Dec 9, 2025
Vor Biopharma Files 8-K — Nov 12, 2025 Risk: low
Vor Biopharma Inc. filed an 8-K on November 12, 2025, reporting on events that occurred on November 10, 2025. The filing primarily concerns 'Other Events' and '
Vor Biopharma Announces Board and Executive Changes — Nov 3, 2025 Risk: medium
Vor Biopharma Inc. announced on November 2, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of
Vor Biopharma Files 8-K for Disclosures — Oct 28, 2025 Risk: low
Vor Biopharma Inc. filed an 8-K on October 28, 2025, to report on Regulation FD disclosures and file financial statements and exhibits. The filing does not cont
Vor Biopharma Files 8-K: Rights Modifications & Other Events — Sep 17, 2025 Risk: medium
On September 17, 2025, Vor Biopharma Inc. filed an 8-K report. The filing indicates material modifications to the rights of security holders and other events, a
Vor Biopharma Files 8-K: Regulation FD & Financials — Sep 2, 2025 Risk: low
Vor Biopharma Inc. filed an 8-K on September 2, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in D
Vor Biopharma Reports Director Changes and Officer Appointments — Aug 27, 2025 Risk: medium
Vor Biopharma Inc. filed an 8-K on August 27, 2025, reporting on several key events as of August 25, 2025. These include the departure of directors or certain o
Vor Biopharma Appoints New Director, Discloses Officer Compensation — Jul 22, 2025 Risk: low
Vor Biopharma Inc. announced on July 16, 2025, a change in its board of directors. Dr. Christopher Starr has been appointed as a new director, effective immedia
Vor Biopharma Inc. Reports Board and Compensation Changes — Jul 10, 2025 Risk: medium
Vor Biopharma Inc. announced on July 9, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of a
Vor Biopharma Inc. Files 8-K: Agreements, Equity Sales, Officer Changes — Jun 26, 2025 Risk: medium
Vor Biopharma Inc. announced on June 25, 2025, the entry into and termination of material definitive agreements. The company also disclosed unregistered sales o
Vor Biopharma Files 8-K with Corporate Updates — May 23, 2025 Risk: low
Vor Biopharma Inc. filed an 8-K on May 23, 2025, reporting events as of May 22, 2025. The filing indicates amendments to articles of incorporation or bylaws, su
Vor Biopharma Inc. Announces Board and Executive Changes — May 20, 2025 Risk: medium
Vor Biopharma Inc. announced on May 19, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of cer
Vor Biopharma Files 8-K: Executive Changes & Restructuring — May 8, 2025 Risk: medium
On May 5, 2025, Vor Biopharma Inc. filed an 8-K report detailing several key events. These include cost-associated exit or disposal activities, the departure of
Vor Biopharma Faces Nasdaq Delisting — Apr 25, 2025 Risk: high
Vor Biopharma Inc. announced on April 22, 2025, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The company
Vor Biopharma Reports Director/Officer Changes — Apr 3, 2025 Risk: medium
Vor Biopharma Inc. filed an 8-K on April 3, 2025, reporting changes effective March 31, 2025. The filing indicates a departure of directors or certain officers,
Vor Biopharma Announces Board and Officer Changes — Feb 6, 2025 Risk: medium
Vor Biopharma Inc. announced on February 3, 2025, changes in its board and officer appointments. Specifically, the company reported the departure of certain off
Vor Biopharma Announces Board and Compensation Changes — Jan 8, 2025 Risk: medium
Vor Biopharma Inc. announced on January 6, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of
Vor Biopharma Files 8-K: Material Agreement & Equity Sales — Dec 27, 2024 Risk: medium
On December 26, 2024, Vor Biopharma Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and pr
8-K Filing — Dec 9, 2024
Vor Biopharma Files 8-K: Officer/Director Changes & Financials — Sep 30, 2024 Risk: medium
Vor Biopharma Inc. filed an 8-K on September 30, 2024, reporting on the departure of directors or certain officers, the election of directors, the appointment o
Vor Biopharma Files 8-K with Updates — Sep 5, 2024 Risk: low
Vor Biopharma Inc. filed an 8-K on September 5, 2024, reporting on events including a Regulation FD Disclosure and Other Events. The filing also includes financ
Vor Biopharma to be Delisted from Nasdaq — Aug 30, 2024 Risk: high
Vor Biopharma Inc. announced on August 29, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The compan
Vor Biopharma Announces Board and Executive Changes — Jun 10, 2024 Risk: medium
Vor Biopharma Inc. announced on June 4, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of cer
Vor Biopharma Files 8-K on Officer/Director Changes & Votes — May 28, 2024 Risk: medium
Vor Biopharma Inc. filed an 8-K on May 28, 2024, reporting events as of May 23, 2024. The filing covers the departure of directors or certain officers, the elec
Vor Biopharma Appoints New CMO & CSO — May 2, 2024 Risk: medium
Vor Biopharma Inc. announced on April 30, 2024, the appointment of Dr. Robert Valeriote as Chief Medical Officer and Dr. David Ma as Chief Scientific Officer. T
Vor Biopharma Files 8-K for 'Other Events' on Jan 5, 2024 — Jan 5, 2024
Vor Biopharma Inc. filed an 8-K on January 5, 2024, indicating an 'Other Events' disclosure. This filing, under SEC File Number 001-39979, simply reports an eve

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX